EUCTR2017-001680-20-GBActive, not recruitingPhase 1
Phase II study of ROS1 targeting with crizotinib in advanced E-cadherin negative, ER positive lobular breast cancer or diffuse gastric cancer - ROLo
Royal Marsden Hospital0 sites58 target enrollmentStarted: June 21, 2018Last updated:
Drugs
Trial Snapshot
- Phase
- Phase 1
- Status
- Active, not recruiting
- Sponsor
- Enrollment
- 58
Study Overview
Brief Summary
No summary available.
Study Design
- Study Type
- Interventional clinical trial of medicinal product
Eligibility Criteria
- Sex
- All
Inclusion Criteria
- •Patients with histologically or Histological diagnosis of inoperable or metastatic diffuse gastric cancer or recurrent inoperable locally advanced ER positive/HER2 negative lobular breast cancer. Assessment of ER and HER2 status as per local assessment.
- •Previously treated with at least one prior line of therapy for advanced disease, but no more than three prior lines of chemotherapy for advanced disease. Patients with breast cancer must have received at least one prior line of hormone therapy for advanced disease
- •Measurable disease (RECIST 1.1)
- •Haematological and biochemical indices within the ranges shown in the protocol. These measurements must be performed within one week (Day -7 to Day 1) before the patient goes in the trial.
- •Female patients with child-bearing potential must have a negative urine or serum pregnancy test within 7 days prior to start of trial. Both male and female patients of reproductive potential must agree to use two forms of highly effective contraception throughout the treatment period and for 90 days after discontinuation of treatment. The oral contraceptive pill may be ineffective when taken with crizotinib so is not an acceptable means of contraception during this study.
- •18 years of age or over with written (signed and dated) informed consent and be capable of co-operating with treatment and follow-up.
- •Eastern Cooperative Oncology Group (ECOG) performance status 0,1 or 2
- •Estimated life expectancy of at least 3 months in the opinion of the investigator
- •Pre-/peri-menopausal breast cancer patients must be willing to receive gosarelin injections every 28 days.
- •Signed and dated informed consent.
- •Patients willing and able to comply with scheduled visits, treatment plans, laboratory tests, and other procedures
- •Are the trial subjects under 18? no
- •Number of subjects for this age range: 0
- •F.1.2 Adults (18-64 years) yes
- •F.1.2.1 Number of subjects for this age range 58
- •F.1.3 Elderly (>=65 years) yes
- •F.1.3.1 Number of subjects for this age range 58
Exclusion Criteria
- •Systemic chemotherapy or investigational medicinal products during the previous four weeks, or hormonal therapy within 7 days except luteinizing hormone-releasing hormone (LHRH) analogues for ovarian suppression. Bisphosphonates or RANK ligand antagonists are permitted for the management of bone metastases.
- •Previous treatment with fulvestrant or any agent that inhibits ROS1
- •Mixed ductal/lobular breast cancer, unless both ductal and lobular components are CDH1 negative by local assessment
- •Major surgery (excluding minor procedures, e.g. placement of vascular access) within 4 weeks or radiation therapy within 14 days prior to study entry
- •Patients with known symptomatic brain metastases requiring steroids, untreated brain metastases or spinal cord compression
- •Any of the following within 12 months prior to study entry: myocardial infarction, uncontrolled angina, coronary/peripheral artery bypass graft, symptomatic congestive heart failure, cerebrovascular accident, or transient ischemic attack. Uncontrolled hypertension or cardiac dysrhythmia including atrial fibrillation
- •QT interval, corrected >470 ms or the use of bradycardic agents, drugs which prolong the QT interval and/or anti-arrhythmic agents within 12 days before the first dose of crizotinib or during study treatment.
- •Use of drugs that are known potent cytochrome P450 (CYP) 3A4 inhibitors or moderate or strong CYP 3A4 inducers within 12 days before the first dose of crizotinib. Us of CYP3A4 substrates with a narrow therapeutic index (such as ciclosporin) is also not permitted within 12 days prior or during the study treatment,.
- •Patients on warfarin. Patients requiring anticoagulation for rate-controlled AF or previous venous thromboembolism should be switched to low-molecular weight heparin.
- •Known HIV or AIDS-related illness, active infection requiring systemic therapy, or positive HBV or HCV test indicating acute or chronic infection
- •Inability or unwillingness to swallow pills, or (for patients receiving fulvestrant) receive IM injections.
- •Other severe acute or chronic medical condition or psychiatric condition, recent or active suicidal ideation or behaviour, or end stage renal disease on haemodialysis, or laboratory abnormality that may increase the risk associated with study participation or investigational products administration or may interfere with the interpretation of results and, in the judgment of the Investigator, would make the patient inappropriate study entry
- •Persisting toxicity related to prior therapy >Grade 1 (except for stable peripheral neuropathy grade =2 or alopecia grade =2).
- •Pregnancy or lactation.
- •Diagnosis of other malignancy within 5 years, except for adequately treated basal cell or squamous cell skin cancer, or carcinoma in situ of the breast or cervix, or low-grade (Gleason =6) prostate cancer
- •Is a participant or plans to participate in another interventional clinical trial, whilst taking part in this study. Participation in an observational trial would be acceptable.
- •Immunocompromised status due to current known active infection with HIV or due to the use of immunosuppressive therapies for other conditions
- •Known prior or suspected hypersensitivity to investigational products
- •Any other condition which in the Investigator’s opinion would not make the patient a good candidate for the clinical trial.
Investigators
Similar Trials
Completed
Phase 2
Crizotinib in Lobular Breast, Diffuse Gastric and Triple Negative Lobular Breast Cancer or CDH1-mutated Solid TumoursLobular Breast CarcinomaGastric CancerTriple Negative Breast CancerCDH1 Gene MutationNCT03620643Royal Marsden NHS Foundation Trust33
Recruiting
Not Applicable
Real-world outcome of crizotinib in ROS1-rearranged non-small cell lung cancer patientsKCT0005014Asan Medical Center30
Unknown
Phase 2
PF-06463922 for Crizotinib Pretreated ROS1 Positive Non-small-cell Lung CancerCarcinoma, Non-Small-Cell LungNCT03439215Fondazione Ricerca Traslazionale20
Active, not recruiting
Phase 1
PF-06463922 for crizotinib pretreated ROS1 positive non-small-cell lung cancer: a phase II Trial (PFROST)ROS1 positive non-small-cell lung cancerMedDRA version: 21.1Level: PTClassification code 10061873Term: Non-small cell lung cancerSystem Organ Class: 10029104 - Neoplasms benign, malignant and unspecified (incl cysts and polyps)EUCTR2016-001259-34-ITFONDAZIONE RICERCA TRASLAZIONALE (FORT)20
Completed
Phase 1
A phase I/II study of crizotinib for recurrent or refractory anaplastic lymphoma kinase (ALK)-positive anaplastic large cell lymphoma (ALCL) and phase I study of this drug for recurrent or refractory neuroblastomaJPRN-UMIN000028075St. Marianna University School of Medicine Hospital National Center for Child Health and Development Nagoya Medical Center Kyushu University Hospital23